Effect of Xuebijing injection on myocardium during cardiopulmonary bypass: A prospective, randomized, double blind trial

Table 1 Baseline characteristics of patients allocated to the Xuebijing injection and control (saline) groups

	Saline group (n = 30)	XBJ group (n = 30)	P value
Age (yr)	57.4 ± 5.3	56.8 ± 6.2	0.69
Male	18	20
Weight (kg)	63.6 ± 5.8	65.4 ± 5.6	0.22
Diabetes mellitus (n)	5	7	0.44
Preoperative LVEF (%)	51.7 ± 8.5	52.5 ± 7.6	0.71
Ejection fraction	50.2 ± 3.2	50.3 ± 3.8	0.91
Preoperative medications (n)
β-blockers	8	6	0.54
Calcium channel blockers	5	7	0.52
Renin angiotensin system inhibitors	5	3	0.44
Statin	4	2	0.39
Digoxin	6	8	0.54
Diuretics	16	19	0.43
Surgical procedure (n)
Aortic valve replacement	8	11	0.40
Mitral valve replacement	10	9	0.78
Tricuspid annuloplasty	12	10	0.59
Pulmonary function test
FVC; % predicted	82.8 ± 7.4	81.9 ± 8.1	0.65
Operation time (min)	257 ± 38	271 ± 41	0.17
CPB time (min)	104 ± 31	111 ± 27	0.35
Intraoperative fluid balance (mL)	2138 ± 348	2215 ± 387	0.42

Data are expressed as mean ± SD (normally distributed data) or median (interquartile range). Chi-square analysis was used for categorical variables, independent t test for normally distributed data. FVC: Forced vital capacity; LVEF: Left ventricular ejection fraction; XBJ: Xuebijing injection.